Trials / Active Not Recruiting
Active Not RecruitingNCT05824481
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
A Phase II Trial of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- Sponsor
- Sun Yat-sen University · Academic / Other
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multi-center Phase II study of cadonilimab (AK104) combined with lenvatinib in patients with advanced endometrial cancer. The primary objective is to evaluate objective response rate of cadonilimab plus lenvatinib.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cadonilimab | Injectable solution |
| DRUG | Lenvatinib | Capsule |
Timeline
- Start date
- 2023-05-08
- Primary completion
- 2025-07-31
- Completion
- 2026-06-30
- First posted
- 2023-04-21
- Last updated
- 2026-03-10
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05824481. Inclusion in this directory is not an endorsement.